Stem Cell Therapeutics Changes Its Name to Trillium Therapeutics Inc.
June 02 2014 - 9:00AM
Marketwired
Stem Cell Therapeutics Changes Its Name to Trillium Therapeutics
Inc.
TORONTO, ONTARIO--(Marketwired - Jun 2, 2014) - Stem Cell
Therapeutics Corp. ("SCT") (TSX:SSS)(OTCQX:SCTPF), an
immuno-oncology company developing innovative therapies for the
treatment of cancer, today announced that it has filed articles of
amalgamation to merge with its wholly-owned subsidiary Trillium
Therapeutics Inc. ("TTI"). The combined company has adopted the
Trillium name.
"The use of "Stem Cell" in our company name did not properly
reflect our business, which is strongly focused on the
immuno-oncology area, such as our checkpoint inhibitor program
targeting the CD47/SIRPa immunoregulatory axis," commented Dr.
Niclas Stiernholm, Chief Executive Officer. "Trillium enjoyed a
solid reputation in the biopharmaceutical industry for its high
quality immunotherapy research, exemplified by a decade of strong
industry and academic partnerships. We will clearly benefit from
this brand recognition with our return to the Trillium name."
Conditional approval for the name change was received from the
TSX. The Company will soon begin trading under the symbol "TR".
About Trillium Therapeutics:
Trillium Therapeutics Inc. is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
Company has two premier preclinical programs, SIRPaFc and a CD200
monoclonal antibody (mAb), which target two key immunoregulatory
pathways that tumor cells exploit to evade the host immune system.
SIRPaFc is an antibody-like fusion protein that blocks the activity
of CD47, a molecule that is upregulated on tumor cells in acute
myeloid leukemia (AML) and numerous other malignancies. The CD200
mAb is a fully human monoclonal antibody that blocks the activity
of CD200, an immunosuppressive molecule that is overexpressed by
many hematopoietic and solid tumors. TTI's clinical stage programs
include tigecycline which is being evaluated in a multi-centre
Phase I study in patients with AML and TTI-1612, which has been
tested in a 28-patient Phase I trial in interstitial cystitis
("IC") patients. For more information, visit:
www.trilliumtherapeutics.com.
Caution Regarding Forward-Looking Information:
This press release may contain forward-looking statements, which
reflect TTI's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may
cause actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements. Such factors include
changing market conditions; the successful and timely completion of
pre-clinical and clinical studies; the establishment of corporate
alliances; the impact of competitive products and pricing; new
product development risks; uncertainties related to the regulatory
approval process or the ability to obtain drug product in
sufficient quantity or at standards acceptable to health regulatory
authorities to complete clinical trials or to meet commercial
demand; and other risks detailed from time to time in TTI's ongoing
quarterly and annual reporting. Except as required by applicable
securities laws, TTI undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neither TSX nor its Regulation Services Provider (as that term
is defined in the policies of the TSX) accepts responsibility for
the adequacy or accuracy of this release.
Trillium Therapeutics Inc.James ParsonsChief Financial Officer+1
416 595
0627james@trilliumtherapeutics.comwww.trilliumtherapeutics.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Sep 2023 to Sep 2024